The test adds to a growing menu of approved assays for the cobas 4800 system.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
The CTC-based oncology diagnostics firm raised $15.6 million in net proceeds from a public offering of its securities in February.
The assays use specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour.
The firm received CLIA waiver of a strep A assay on its Liat platform yesterday, and a favorable evaluation of its influenza A/B assay was published last week.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.
Adam Rutherford discusses genetic genealogy at the Guardian.
Portions of the US 21st Century Cures Act are raising some safety concerns.
David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.